ERBB2 and neoplasm: For the breast tumours classified as basal-like tumours, 5 out of 7 had no ER, PR or ErbB2 overexpression (‘triple negative’), whereas only 4 out of 52 non-basal-like breast tumours were triple negative (Pearson χ2, P<0.0001).